Navigation Links
HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter
Date:1/18/2013

Ponte Vedra Beach, Florida (PRWEB) January 18, 2013

Today’s Newsletter from HealthEconomics.Com covers a fascinating overview of the history of evidence-based medicine (EBM), and describes the role of the patient in interpreting and applying EBM to their own health care. The article also discusses the physician’s dilemma of choosing either an evidence-based treatment plan that is based on population impact or one that predominantly considers the individual patient. Which is correct? The original article was sourced from the January issue of the American Medical Association Journal of Ethics.

Are drug price cuts to achieve reimbursement in the United Kingdom actually undermining pharma’s value story for their drug products, or is this tactic helping to bolster the cost-effectiveness story? Another top story reports Lucentis (ranibizumab) for impaired sight in some patients with diabetic macular edema has now won the backing of NICE, after the makers of the drug agreed to discount the price and provide additional evidence of efficacy. The story, originally published by Bloomberg, is covered in HealthEconomics.Com News.

How is the second Obama Administration going to affect healthcare access, payment reform, Medicare, Medicaid, healthcare quality initiatives, and the pharmaceutical industry? In an article by PharmaPro.Com, key issues are outlined. Some challenges pre-date the Affordable Care Act (ACA) and others have been caused by the passage of the ACA. Challenges include an undetermined impact of the individual mandate, reduced patient access to physicians, increased medical care wait times, and expansion of state Medicaid programs. The steps that the pharmaceutical industry needs to take to succeed in this post-election arena are detailed in this article on HealthEconomics.Com.

About HealthEconomics.Com: A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.
News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by clicking on the following link: Subscribe to HealthEconomics.Com Newsletter.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10332724.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
6. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
7. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
8. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
9. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
10. Fusion presents low proliferation risk, experts conclude
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):